Now Available for Public Comment: Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials

Influence of Angiotensin Converting Enzyme (ACE) Genotype on Lung Diffusion in Heart Failure

The recruitment status of this study is unknown because the information has not been verified recently.
Verified August 2006 by Centro Cardiologico Monzino.
Recruitment status was  Recruiting
Sponsor:
Information provided by:
Centro Cardiologico Monzino
ClinicalTrials.gov Identifier:
NCT00361127
First received: August 4, 2006
Last updated: October 19, 2006
Last verified: August 2006

August 4, 2006
October 19, 2006
August 2006
Not Provided
Possible identification of a genetic pattern responsible for different responses to ACE-inhibition during fluid overload in heart failure
Possible identification of a genetic pattern responsible for different response to ACE-inhibition during fluid overload in heart failure.
Complete list of historical versions of study NCT00361127 on ClinicalTrials.gov Archive Site
  • Influence of ACE-genotype on exercise capacity
  • Influence of ACE-genotype on lung function
Same as current
Not Provided
Not Provided
 
Influence of Angiotensin Converting Enzyme (ACE) Genotype on Lung Diffusion in Heart Failure
Influence of ACE Genotype on Lung Diffusion at Rest and After Fluid Overload in Heart Failure Patients Treated With ACE-Inhibitors

In patients with chronic heart failure ACE-inhibitor treatment improves lung diffusion and prevents pulmonary edema after fluid overload. In the western country, 3 population types of ACE genotypes exist (DD, ID, II). It is unknown whether the ACE genotype influences the response to fluid overload in ACE-inhibitor treated chronic heart failure patients.

Patients with chronic heart failure in stable clinical condition treated with ACE-inhibitors, but not aspirin, will be evaluated by means of maximal cardiopulmonary exercise test and lung function including lung diffusion measurements. These tests will be done before and after rapid 500 ml isotonic saline infusion. Patients will be grouped according to their ACE genotype.

Interventional
Not Provided
Allocation: Non-Randomized
Endpoint Classification: Safety Study
Intervention Model: Single Group Assignment
Masking: Open Label
Primary Purpose: Prevention
Heart Failure, Congestive
Drug: isotonic saline infusion
Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Recruiting
50
August 2006
Not Provided

Inclusion Criteria:

  • New York Heart Association (NYHA) class I and II heart failure
  • Chronic ACE-inhibitor treatment

Exclusion Criteria:

  • Aspirin treatment in the previous 2 months
Both
20 Years to 80 Years
No
Contact: Piergiuseppe Agostoni, MD-PhD +39 02 58002299 piergiuseppe.agostoni@ccfm.it
Contact: Mauro Contini, MD +39 02 58002525 mauro.contini@ccfm.it
Italy
 
NCT00361127
CCM S65/206
Not Provided
Not Provided
Centro Cardiologico Monzino
Not Provided
Principal Investigator: Piergiuseppe Agostoni, MD.PhD Centro Cardiologico Monzino
Centro Cardiologico Monzino
August 2006

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP